Prosecution Insights
Last updated: October 01, 2026
Application No. 18/441,092

PLURALITY OF HOST MATERIALS AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME

Final Rejection §112
Filed
Feb 14, 2024
Priority
Mar 23, 2023 — RE 10-2023-0037814
Examiner
COLEMAN, BRENDA LIBBY
Art Unit
2897
Tech Center
2800 — Semiconductors & Electrical Systems
Assignee
Rohm and Haas Electronic Materials Korea Ltd.
OA Round
2 (Final)
75%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
1230 granted / 1643 resolved
+6.9% vs TC avg
Strong +16% interview lift
Without
With
+15.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
54 currently pending
Career history
1670
Total Applications
across all art units

Statute-Specific Performance

§101
3.4%
-36.6% vs TC avg
§103
8.5%
-31.5% vs TC avg
§102
15.8%
-24.2% vs TC avg
§112
52.8%
+12.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1643 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-8 are pending in the application. This action is in response to applicants' amendment dated August 4, 2026. Claims 1, 3 and 7 have been amended. Response to Amendment Applicant's arguments filed August 4, 2026 have been fully considered with the following effect: The applicant's amendments and arguments are sufficient to overcome the 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph rejections, labeled paragraph 1a), b), c), d), e), r), s), t) and u) in the last office action, which are hereby withdrawn. However, with regards to the 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph rejections, labeled paragraph 1f), g), h), i), j), k), l), m), n), o), p) and q),) of the last office action, the applicant’s amendments and remarks have been fully considered but they are not persuasive. f-n and q) The applicants’ stated that explicit disclosure of every structural feature that a person having ordinary skill in the art would inherently understand to be encompassed by the claim language and that upon reading the claims in light of the specification, would understand the scope of the claimed subject matter with reasonable certainty. However, the claims defined ring A and ring B, each independently represent, a benzene ring or a naphthalene ring; provided that at least one of ring A and ring B is a naphthalene ring. It is herein acknowledged that the claims were read in light of the specification and the definition of ring A and ring B in the claim with the teachings of the specification do not include the substitution of the benzene ring or the naphthyl ring as claimed in the species f) H-106 and H-126 g) H-112 and H-325 h) H-128, H-274, H-281, H-295, H-302, H-315, H-348 and H-480 i) H-144, H-151, H-267, H-280, H-291, H-300 and H-431 j) H-178, H-186, H- 190, H-193, H-203, H-205, H-206, H-207, H-208, H-219, H-229, H-244, H-265, H-306, H-318, H-349, H-357, H-363, H-373, H-378, H-393, H-395, H-428, H-437, H-447, H-460, H-471 and H-484 k) H-195 and H-212 l) H-311 m) H-316 n) H-35 and q) H-442. Each of these species contain substitution on ring A or ring B beyond the -L1-N(Ar1)(Ar2) which is not being claimed in the genus of Formula 1. Claim 6 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, for reasons of record and stated above. o) The applicants’ stated that explicit disclosure of every structural feature that a person having ordinary skill in the art would inherently understand to be encompassed by the claim language and that upon reading the claims in light of the specification, would understand the scope of the claimed subject matter with reasonable certainty. However, the claims defined Ar1 as a deuterium-substituted or unsubstituted (C6-C30) aryl or a substituted or unsubstituted (3- to 30-membered) heteroaryl selected from the group consisting of dibenzothiophenyl, dibenzofuranyl, benzothiophenyl, benzofuranyl and indolyl. It is herein acknowledged that the claims were read in light of the specification and the definition of Ar1 in the claim with the teachings of the specification do not include the substituent PNG media_image1.png 83 59 media_image1.png Greyscale as claimed in the species H-417. Claim 6 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, for reasons of record and stated above. p) The applicants’ stated that explicit disclosure of every structural feature that a person having ordinary skill in the art would inherently understand to be encompassed by the claim language and that upon reading the claims in light of the specification, would understand the scope of the claimed subject matter with reasonable certainty. However, the claims defined the substituent -L1-N(Ar1)(Ar2) on the B ring not as a substituent of the R1 variable. It is herein acknowledged that the claims were read in light of the specification and the compounds of Formula 1 do not include the substitution of the R1 variable is the point of attachment of the substituent -L1-N(Ar1)(Ar2) as claimed in the species H-423. Claim 6 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, for reasons of record and stated above. The applicant's amendments and arguments are sufficient to overcome the 35 U.S.C. 102(a)(1), anticipation rejection, labeled paragraph 2) in the last office action, which is hereby withdrawn. The applicant's amendments and arguments are sufficient to overcome the 35 U.S.C. 102(a)(1), anticipation rejection, labeled paragraph 3) in the last office action, which is hereby withdrawn. The applicant's filing of terminal disclaimers is sufficient to overcome the nonstatutory double patenting rejections, labeled paragraphs 4), 5), 6), 7), 8), 9), 10), 11) and 12) in the last office action, which are hereby withdrawn. In view of the amendment dated August 4, 2026, the following new grounds of rejection apply: Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION. —The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 3 and 6 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. The following reasons apply: Claim 3 is vague and indefinite in that it is not known what is meant by “may be the same or different” for the variables R13, R14 and R15 wherein the variables are only hydrogen. Claim 6 recites the limitation " PNG media_image2.png 112 75 media_image2.png Greyscale " in H-22 with respect to Ar-1 or Ar2. There is insufficient antecedent basis for this limitation in the claim. Claim 6 recites the limitation " PNG media_image3.png 77 72 media_image3.png Greyscale " in H-23, H-37, H-55, H-164, H-411 and H-465 with respect to Ar-1 or Ar2. There is insufficient antecedent basis for this limitation in the claim. Claim 6 recites the limitation " PNG media_image4.png 93 79 media_image4.png Greyscale " in H-81 with respect to Ar-1 or Ar2. There is insufficient antecedent basis for this limitation in the claim. Claim 6 recites the limitation " PNG media_image5.png 42 103 media_image5.png Greyscale " in H-97 with respect to Ar-1 or Ar2. There is insufficient antecedent basis for this limitation in the claim. Claim 6 recites the limitation " PNG media_image6.png 95 95 media_image6.png Greyscale " in H-101 with respect to Ar-1 or Ar2. There is insufficient antecedent basis for this limitation in the claim. Claim 6 recites the limitation " PNG media_image7.png 98 92 media_image7.png Greyscale " in H-132 and H-467 with respect to Ar-1 or Ar2. There is insufficient antecedent basis for this limitation in the claim. Claim 6 recites the limitation " PNG media_image8.png 51 124 media_image8.png Greyscale " in H-194 with respect to Ar-1 or Ar2. There is insufficient antecedent basis for this limitation in the claim. Claim 6 recites the limitation " PNG media_image9.png 113 71 media_image9.png Greyscale " in H-468 with respect to -L1-N(Ar-1)(Ar2). There is insufficient antecedent basis for this limitation in the claim. Claim Objections Claim 1 is objected to because of the following informalities: there is a period at the end of the third line of the claim indicating the end of the claim which is not so. Appropriate correction is required. Claims 2, 4, 5, 7 and 8 are objected to as being dependent upon an objected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRENDA L COLEMAN whose telephone number is (571)272-0665. The examiner can normally be reached Mon-Fri 10-6 (flex). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey H. Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRENDA L COLEMAN/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Feb 14, 2024
Application Filed
May 04, 2026
Non-Final Rejection mailed — §112
Aug 04, 2026
Response Filed
Aug 25, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12740961
USE OF AN ORGANOMETALLIC COMPOUND AS A DNA-DEMETHYLATING AGENT
5y 4m to grant Granted Sep 22, 2026
Patent 12723055
PHOSPHOANTIGEN PRODRUG COMPOUNDS
5y 8m to grant Granted Sep 01, 2026
Patent 12723038
ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE
3y 6m to grant Granted Sep 01, 2026
Patent 12708629
METHODS AND COMPOSITIONS FOR REDUCING PARATHYROID LEVELS
3y 3m to grant Granted Aug 18, 2026
Patent 12709621
TYK2 INHIBITORS
3y 1m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
75%
Grant Probability
90%
With Interview (+15.5%)
2y 5m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1643 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month